삼출성연령관련황반변성에서 유리체강내라니비주맙치료에 의한 시력 호전 정도와 흡연의 관계

Abstract

학위논문 (석사)-- 서울대학교 대학원 : 임상의과학과, 2013. 2. 유형곤.Introduction: In this study, the risk factors that may influence visual improvement after intravitreal ranibizumab (IVR) treatment for exudative age-related macular degeneration (AMD) were examined. Patients and Methods: From April 2008 to February 2012, 420 patients (448 eyes) with exudative AMD were prospectively registered at Seoul National University Hospital. From this group of patients, 125 eyes were included in this study. All patients were treated with 3 consecutive IVR injections. The best-corrected visual acuity (VA) was evaluated at baseline and 1 month after the third ranibizumab injection. To evaluate the risk factors associated with VA improvement after IVR, patient demographic data and systemic risk factors were analyzed. Patients were divided into a nonresponder group and a responder group, with reference to the median visual improvement in all eyes. Results: Among 125 eyes, 66 eyes (52.8%) were included in the responder group and 59 eyes (47.2%) in the non-responder group. The median VA improvement after 3 monthly ranibizumab injections was -0.05 logMAR. Multivariate analyses revealed that current smoking (adjusted OR, 7.54095% CI, 1.732–32.823) was independently associated with poor VA improvement after IVR treatment for exudative AMD. Conclusion: Cigarette smoking is an independent risk factor for lower VA gains with IVR treatment for exudative AMD. Therefore, we believe that smoking cessation is important for a better visual outcome in AMD patients who are current smokers.I. Introduction 1 II. Materials and Methods 2 III. Results 5 IV. Discussion 13 V. Reference 17 국문 초록 21Maste